<code id='EC09910A80'></code><style id='EC09910A80'></style>
    • <acronym id='EC09910A80'></acronym>
      <center id='EC09910A80'><center id='EC09910A80'><tfoot id='EC09910A80'></tfoot></center><abbr id='EC09910A80'><dir id='EC09910A80'><tfoot id='EC09910A80'></tfoot><noframes id='EC09910A80'>

    • <optgroup id='EC09910A80'><strike id='EC09910A80'><sup id='EC09910A80'></sup></strike><code id='EC09910A80'></code></optgroup>
        1. <b id='EC09910A80'><label id='EC09910A80'><select id='EC09910A80'><dt id='EC09910A80'><span id='EC09910A80'></span></dt></select></label></b><u id='EC09910A80'></u>
          <i id='EC09910A80'><strike id='EC09910A80'><tt id='EC09910A80'><pre id='EC09910A80'></pre></tt></strike></i>

          
          WSS
          Brain cancer
          Michelle Monje/Stanford University/NIH

          Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

          The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

          advertisement

          “We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion